awmsg logo

epoetin alfa (Binocrit®)

Reference No. 397

Publication date:

Appraisal information

epoetin alfa (Binocrit®) solution for injection

Company: Sandoz Ltd
BNF category: Nutrition and blood
NMG meeting date: 14/07/2010
AWMSG meeting date: 18/08/2010
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1210
Ratification by Welsh Government: 20/09/2010

Current Progress

Ratification by
Welsh Government

AWMSG advice

Epoetin alfa (Binocrit®) is recommended as an option for restricted use within NHS Wales in accordance with NICE Clinical Guideline 39 for the treatment of symptomatic anaemia associated with chronic renal failure in adult and paediatric patients: - Treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis. - Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Epoetin alfa (Binocrit®) is not suitable for shared care within NHS Wales for the above indications. Epoetin alfa (Binocrit®) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.
Final Appraisal Recommendation (FAR)